Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn
Topics & Concepts
AtezolizumabBevacizumabMedicineSorafenibInternal medicineHazard ratioHepatocellular carcinomaOncologyPopulationClinical endpointProgression-free survivalGastroenterologySurgeryRandomized controlled trialCancerConfidence intervalChemotherapyNivolumabImmunotherapyEnvironmental healthHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesCancer Mechanisms and Therapy